BiotechTube

Fufangdanshen Tablets + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vascular Dementia

Conditions

Vascular Dementia

Trial Timeline

Sep 1, 2012 → Dec 1, 2015

NCT ID
NCT01761227

About Fufangdanshen Tablets + Placebo

Fufangdanshen Tablets + Placebo is a phase 2 stage product being developed by Guangzhou Baiyunshan Pharmaceutical Holdings for Vascular Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT01761227. Target conditions include Vascular Dementia.

What happened to similar drugs?

20 of 20 similar drugs in Vascular Dementia were approved

Approved (20) Terminated (1) Active (0)
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
✅donepezil hydrochloride (Aricept)EisaiApproved
✅Lorcaserin hydrochloride + PlaceboEisaiApproved
✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01761227Phase 2Completed

Competing Products

20 competing products in Vascular Dementia

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
olmesartanDaiichi SankyoPre-clinical
26
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
LexiscanAstellas PharmaPhase 2
35
YM872 (zonampanel)Astellas PharmaPhase 2
35